Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer

Prostate Cancer and Prostatic Diseases, Published online: 22 February 2024; doi:10.1038/s41391-024-00811-5Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer

Source: Prostate Cancer and Prostatic Diseases - February 22, 2024 Category: Urology & Nephrology Authors: Ryan E. Fecteau Bridget F. Koontz Karen E. Hoffman Susan Halabi Lauren E. Howard Monika Anand Daniel J. George Tian Zhang William R. Berry W. Robert Lee Michael R. Harrison Paul G. Corn Andrew J. Armstrong Source Type: research